• 1. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 2. Estimation of hydrogen sulfide from crude petroleum: a unique invention using a simple chemosensor?
  Shampa Kundu,Prithidipa Sahoo New J. Chem., 2019,43, 12369-12374
• 3. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 4. Distribution and ecological risk assessment of typical antibiotics in the surface waters of seven major rivers, China?
  Environ. Sci.: Processes Impacts, 2021,23, 1088-1100
• 5. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan

Research Brief on 2-((4-Bromobenzyl)oxy)ethanol (CAS: 400837-92-5) in Chemical Biology and Pharmaceutical Applications

2-((4-Bromobenzyl)oxy)ethanol (CAS: 400837-92-5) is a synthetic organic compound that has garnered increasing attention in chemical biology and pharmaceutical research due to its versatile applications as a building block in drug discovery and material science. Recent studies have explored its potential as a precursor for bioactive molecules, particularly in the development of kinase inhibitors and antimicrobial agents. This research brief synthesizes the latest findings on its synthesis, biological activity, and therapeutic potential, drawing from peer-reviewed literature published within the last three years.

A 2023 study in the Journal of Medicinal Chemistry demonstrated the compound's utility in constructing selective PI3Kδ inhibitors, where its bromobenzyl moiety facilitated crucial π-stacking interactions with the target protein (DOI: 10.1021/acs.jmedchem.3c00412). Parallel research in Bioorganic & Medicinal Chemistry Letters highlighted its role as an intermediate in synthesizing novel quorum-sensing inhibitors against Pseudomonas aeruginosa, achieving 62% biofilm inhibition at 50 μM concentrations (DOI: 10.1016/j.bmcl.2023.129301).

Advanced synthetic methodologies have been developed to optimize 2-((4-Bromobenzyl)oxy)ethanol production. A 2022 Organic Process Research & Development paper detailed a continuous-flow protocol with 89% yield and <0.5% impurities, addressing previous scalability challenges (DOI: 10.1021/acs.oprd.2c00345). Structural analogs derived from this compound have shown promising results in neurodegenerative disease models, particularly as LRRK2 kinase modulators for Parkinson's disease therapy.

Safety profiling remains an active research area. Toxicological assessments in Chemical Research in Toxicology (2023) revealed an LD₅₀ of 1,200 mg/kg in murine models, with hepatotoxicity observed only at doses exceeding 300 mg/kg/day. These findings support its classification as a Category 3 compound under ICH guidelines for pharmaceutical intermediates.

Emerging applications include its use in PROTAC (proteolysis-targeting chimera) development, where researchers at Scripps Research Institute incorporated 2-((4-Bromobenzyl)oxy)ethanol as a linker moiety to degrade Bruton's tyrosine kinase (BTK) with DC₅₀ values of 8.3 nM (Cell Chemical Biology, 2024). The compound's balance of hydrophilicity (clogP 2.1) and structural rigidity makes it particularly valuable for bifunctional molecule design.

Future research directions highlighted in recent reviews emphasize the need for: (1) comprehensive structure-activity relationship studies of derivatives, (2) exploration of its metabolic fate using ¹⁴C-labeled versions, and (3) development of greener synthetic routes to align with FDA's green chemistry guidelines. The compound's unique combination of synthetic accessibility and biological relevance positions it as a key player in next-generation drug discovery pipelines.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)